Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker Corporation (Nasdaq: BRKR) has unveiled enhanced capabilities for proteomic and epiproteomic analysis using its innovative TIMScore™ algorithm integrated into the PaSER 2022 system. This new technology allows for the identification of over 8000 protein groups in just 35 minutes while improving phosphopeptide identification by more than 25%. With access to ultra-deep libraries of over 13,000 protein groups, the TIMScore™ algorithm enhances peptide confidence and coverage, supporting high-throughput translational proteomics.
Bruker Corporation (NASDAQ: BRKR) has announced the appointment of Philip Ma, Ph.D., to its Board of Directors, effective April 1, 2022. Dr. Ma is the CEO and founder of PrognomiQ and has significant experience in life sciences, particularly in multiomics and cancer diagnostics. His previous roles include leadership positions at Biogen and McKinsey & Company. The company aims to leverage his expertise to advance its Project Accelerate 2.0 initiatives, which focus on enhancing life science and clinical research tools.
Bruker Corporation (NASDAQ: BRKR) announced enhanced capabilities for its Fourier 80 benchtop FT-NMR spectrometer, now featuring an Adjustable Temperature option for samples between 25°C to 60°C. This upgrade expands applications in pharmaceutical and food analysis, improving synthesis and process control. The introduction of the RxnLab™ solution offers temperature-controlled monitoring of reactions, while the Olive Oil-Profiling™ 1.0 solution supports olive oil authenticity analysis. The enhancements aim to elevate research capabilities in various analytical laboratories.
Canopy Biosciences, a Bruker Company, launched the CellScape™ System, enhancing ChipCytometry technology for high-plex spatial proteomics. This new benchtop system improves automation, optical performance, and throughput, enabling researchers to analyze millions of cells with single-cell resolution. Since the 2020 acquisition by Bruker, Canopy has advanced its capabilities, setting a new standard in spatial biology research. The CellScape™ is designed for large-scale clinical studies and is compatible with standard fluorescently labeled antibodies, fostering streamlined workflows in immunology and other fields.
Bruker Corporation (NASDAQ: BRKR) and Newomics Inc. announced a co-marketing collaboration focused on a novel LC-MS platform for drug discovery in pharma and biopharma. The partnership will integrate Newomics’ Microflow-nanospray Electrospray Ionization (MnESI) products with Bruker’s mass spectrometers, enhancing isotopic fidelity and sensitivity for biological sample analysis. Both companies highlight their successful R&D collaborations and the potential for improved results in biopharmaceutical and clinical research.
Bruker Corporation (Nasdaq: BRKR) will participate in Cowen’s 42nd Annual Health Care Conference from March 7-9, 2022. Gerald Herman, Executive VP & CFO, will present on March 7, 2022, at 2:50 PM EST. A live webcast of the presentation will be accessible on the Company’s Investor Relations website, with a replay available for 90 days post-event. Bruker specializes in high-performance scientific instruments and solutions that enhance life sciences and diagnostics, empowering scientific breakthroughs.
Bruker Corporation has announced an increase in its quarterly cash dividend to
Bruker Corporation (Nasdaq: BRKR) reported Q4 2021 revenues of $683.5 million, an increase of 8.9% year-over-year, with organic growth of 11.4%. FY 2021 revenues reached $2.42 billion, up 21.7%, with non-GAAP EPS rising 55.6% to $2.10. For FY 2022, Bruker expects revenue growth between 5% to 7%, and non-GAAP EPS guidance of $2.29 to $2.33, reflecting solid performance despite ongoing supply chain challenges. Significant investments in Project Accelerate 2.0 focus on proteomics and spatial biology are expected to drive future growth.
Bruker Corporation (Nasdaq: BRKR) will participate in the 11th Annual SVB Leerink Global Healthcare Conference virtually on February 16, 2022, at 8:40 AM EST. Frank Laukien, Chairman, President & CEO, will represent the company. Interested parties can access a live audio webcast on the Investor Relations section of Bruker's website. A replay will be available for 30 days post-event. Bruker specializes in high-performance scientific instruments and solutions for life sciences and diagnostics, contributing to advancements in molecular and cellular research.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
